Ravindra Uppaluri, MD, PhD, discussed the KEYNOTE-689 trial, which investigated pembrolizumab in locally advanced head and ...

Residual nodal disease following neoadjuvant chemotherapy for upper tract urothelial carcinoma (UTUC) indicates an especially high-risk population.

Lymph node metastasis was uncommon among clinically node-negative PTC patients without evidence of nodal involvement on USG and CT.

Ravindra Uppaluri, MD, PhD, lead investigator of the phase 3 KEYNOTE-689 trial (NCT03765918), highlights the potential of pembrolizumab (Keytruda; Merck) to improve outcomes following head and neck ...